Dangerous Drug: Irinotecan Hydrochloride(eh rin oh’ te kan)
Camptosar
PREGNANCY CATEGORY D
Drug Classes
Antineoplastic
DNA topoisomerase inhibitor
Therapeutic Actions
Cytotoxic: Causes death of cells during cell division by causing damage to the DNA strand during DNA synthesis; specific to cells using topoisomerase I, DNA, and irinotecan complexes.
Indications
-
First-line therapy in combination with 5-FU and leucovorin for patients with metastatic colon or rectal carcinomas
-
Treatment of patients with metastatic colon or rectal cancer whose disease has recurred or progressed following 5-FU therapy
-
Unlabeled uses: Cervical cancer, lung cancer, gastric cancer, CNS tumor
Contraindications and Cautions
-
Contraindicated with allergy to irinotecan, lactation, pregnancy.
-
Use cautiously with bone marrow depression, severe diarrhea.
Available Forms
Injection—20 mg/mL
Dosages
Adults
Monitor patient for toxicity at each visit, and modify dose based on patient tolerance.
-
Single-drug use: 125 mg/m2 IV over 90 min once weekly for 4 wk, then a 2-wk rest; repeat 6-wk regimen or 350 mg/m2 IV over 90 min once every 3 wk.
-
Combination drugs: 125 mg/m2 IV over 90 min, days 1, 8, 15, and 22 with leucovorin 20 mg/m2 IV bolus days 1, 8, 15, and 22 and 5-FU, 500 mg/m2 IV days 1, 8, 15, and 22. Restart cycle on day 43. Or 180 mg/m2 IV over 90 min days 1, 15, and 29 with leucovorin—200 mg/m2 IV over 2 hr days 1, 2, 15, 16, 29, and 30 and 5-FU—400 mg/m2 as IV bolus days 1, 2, 15, 16, 29, and 30 followed by 5-FU 600 mg/m2 IV infusion over 22 hr on days 1, 2, 15, 16, 29, and 30. Restart cycle on day 43.
Pediatric patients
Not recommended.
Pharmacokinetics
|
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
